Related Experiment Video
Updated: Aug 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Blocking tumor necrosis factor-alpha inhibits folic acid-induced acute renal failure
1Joint Immunology Laboratory of Institute of Health Sciences, Chinese Academy of Sciences and Medical College of Shanghai, Jiao Tong University, Shanghai, China.
Abstract:
Systemic administration of mice with folic acid (FA) has been used for studying the pathogenesis of acute renal failure. However, the molecular mechanisms by which FA induces acute renal failure remain poorly understood. We found that CD-1 mice treated with FA developed acute renal failure characterized by increased blood urea nitrogen, necrosis, and apoptosis of tubular epithelial cells. Compared to control mice, tumor necrosis factor-alpha (TNF-alpha) was markedly elevated in blood and kidneys of these FA-treated mice, accompanied by markedly reduced expression of anti-apoptotic protein BclxL in their kidneys. In vivo administration of FA-treated CD-1 mice with neutralizing anti-TNF-alpha antibody restored the expression of BclxL in kidneys and inhibited the necrosis and apoptosis of renal tubular epithelial cells, leading to the amelioration of acute renal failure. In ex vivo cultures, we found that FA enhanced production of TNF-alpha, decreased expression of BclxL protein, and induced apoptosis of mouse cortical tubule (MCT) cells. Addition of neutralizing anti-TNF-alpha antibody, but not control IgG, in the cultures markedly blocked the apoptotic death of FA-treated MCT cells and restored expression of BclxL to the same levels as those MCT cells cultured in the absence of FA. All these results suggest that TNF-alpha is a critical inflammatory cytokine responsible for FA-mediated acute renal failure. Furthermore, in vivo administration of anti-TNF-alpha antibody may be proved as an effective approach for acute renal failure prevention and treatment.
Insights
Folic acid (FA) causes acute kidney injury by increasing tumor necrosis factor-alpha (TNF-alpha), which triggers cell death. Blocking TNF-alpha with an antibody protects against FA-induced kidney damage.
Area of Science:
- Nephrology
- Toxicology
- Immunology
Background:
- Folic acid (FA) administration is a model for studying acute renal failure (ARF).
- The precise molecular mechanisms underlying FA-induced ARF are not fully elucidated.
Purpose of the Study:
- To investigate the role of tumor necrosis factor-alpha (TNF-alpha) in FA-induced acute renal failure.
- To explore the potential therapeutic effect of anti-TNF-alpha antibody in FA-mediated kidney injury.
Main Methods:
- Systemic administration of folic acid to CD-1 mice to induce acute renal failure.
- Measurement of blood urea nitrogen (BUN), histological analysis (necrosis, apoptosis), and assessment of TNF-alpha and BclxL expression.
- In vivo and ex vivo experiments using neutralizing anti-TNF-alpha antibody treatment.
Main Results:
- FA-treated mice exhibited elevated BUN, renal tubular necrosis, and apoptosis.
- Increased TNF-alpha and decreased BclxL expression were observed in kidneys of FA-treated mice.
- Anti-TNF-alpha antibody treatment ameliorated FA-induced ARF by restoring BclxL and inhibiting apoptosis.
Conclusions:
- TNF-alpha is a key inflammatory mediator in folic acid-induced acute renal failure.
- Neutralizing anti-TNF-alpha antibody shows promise as a therapeutic strategy for preventing and treating FA-mediated ARF.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Kidney Injury I: Introduction
